Association of serum [alpha]-tocopherol, [beta]-carotene, and retinol with liver cancer incidence and chronic liver disease mortality
Menée à partir d'échantillons sériques prélevés sur 29 046 puis 22 805 hommes (durée de suivi : 24 ans), cette étude évalue l'association entre les niveaux de l'alpha-
Background : Micronutrients may influence the development or progression of liver cancer and liver disease. We evaluated the association of serum
α-tocopherol, β-carotene, and retinol with incident liver cancer and chronic liver disease (CLD) mortality in a prospective cohort of middle-aged Finnish male smokers.
Methods
:
Baseline and 3-year follow-up serum were available from 29
046 and 22 805 men, respectively. After 24 years of follow-up, 208 men were diagnosed with liver cancer and 237 died from CLD. Hazards ratios and 95% confidence intervals were calculated for highest vs lowest quartiles from multivariate proportional hazards models.
Results : Higher
β-carotene and retinol levels were associated with less liver cancer (β-carotene: 0.35, 0.22
–0.55, P-trend <0.0001; retinol: 0.58, 0.39–0.85, P-trend=0.0009) and CLD mortality (
β-carotene: 0.47, 0.30
–0.75, P-trend=0.001; retinol: 0.55, 0.38–0.78, P-trend=0.0007).
α-Tocopherol was associated with CLD mortality (0.63, 0.40
–0.99, P-trend=0.06), but not with liver cancer (1.06, 0.64–1.74, P-trend=0.77). Participants with higher levels of
β-carotene and retinol, but not α-tocopherol, at both baseline and year 3 had lower risk of each outcome than those with lower levels.
Conclusions
:
Our findings suggest that higher concentrations of β-carotene and retinol are associated with incident liver cancer and CLD. However, such data do not indicate that supplementation should be considered for these diseases.
British Journal of Cancer , résumé, 2013